Biocon Wins FDA Approval for Pebrilzo Breast Cancer Biosimilar
Bengaluru, Karnataka, India, and Bridgewater, New Jersey, USA, November 16, 2026 Biocon Limited has received approval from the U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Bengaluru, Karnataka, India, and Bridgewater, New Jersey, USA, November 16, 2026 Biocon Limited has received approval from the U.S....
Bengaluru, Karnataka, India, November 18, 2026 Biocon Limited has announced that the European Commission (EC) has granted marketing authorization...
Toronto, Canada & Bengaluru, India, April 21, 2026 In a significant advancement for global biosimilars and bone health therapeutics,...
BENGALURU, India & BRIDGEWATER, New Jersey, United States, April 7, 2026 Biocon Limited announced the U.S. commercial launch of...
CRANBURY, New Jersey, September 11, 2025 — Biocon Limited has inaugurated its first U.S. manufacturing facility in Cranbury, New...
